A camelid antibody fragment inhibits the formation of amyloid fibrils by human lysozyme (Q27641839)

Serge Muyldermans

10

0 references

Chris Dobson

15

Christopher M Dobson

0 references

Carol V. Robinson

14

Carol V Robinson

0 references

Lode Wyns

11

Lode Wyns

0 references

author name string

Mireille Dumoulin

1

0 references

Alexander M Last

2

0 references

Aline Desmyter

3

0 references

Klaas Decanniere

4

0 references

Denis Canet

5

0 references

Göran Larsson

6

0 references

Andrew Spencer

7

0 references

David B Archer

8

0 references

Jurgen Sasse

9

0 references

André Matagne

https://api.crossref.org/works/10.1038%2FNATURE01870

13

0 references

language of work or name

English

0 references

publication date

14 August 2003

0 references

published in

Nature

0 references

volume

424

0 references

issue

6950

0 references

page(s)

783-8

0 references

1 reference

7 January 2021

Amyloid diseases: abnormal protein aggregation in neurodegeneration

1 reference

https://api.crossref.org/works/10.1038%2FNATURE01870

7 January 2021

The structural basis of protein folding and its links with human disease

1 reference

https://api.crossref.org/works/10.1038%2FNATURE01870

7 January 2021

Human lysozyme gene mutations cause hereditary systemic amyloidosis

1 reference

https://api.crossref.org/works/10.1038%2FNATURE01870

7 January 2021

Hereditary renal amyloidosis caused by a new variant lysozyme W64R in a French family

1 reference

https://api.crossref.org/works/10.1038%2FNATURE01870

7 January 2021

A novel lysozyme mutation Phe57Ile associated with hereditary renal amyloidosis

1 reference

https://api.crossref.org/works/10.1038%2FNATURE01870

7 January 2021

Single-domain antibody fragments with high conformational stability

1 reference

https://api.crossref.org/works/10.1038%2FNATURE01870

7 January 2021

Naturally occurring antibodies devoid of light chains

1 reference

https://api.crossref.org/works/10.1038%2FNATURE01870

7 January 2021

Instability, unfolding and aggregation of human lysozyme variants underlying amyloid fibrillogenesis

1 reference

https://api.crossref.org/works/10.1038%2FNATURE01870

7 January 2021

Local cooperativity in the unfolding of an amyloidogenic variant of human lysozyme

1 reference

https://api.crossref.org/works/10.1038%2FNATURE01870

7 January 2021

Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning

1 reference

https://api.crossref.org/works/10.1038%2FNATURE01870

7 January 2021

Antibodies inhibit prion propagation and clear cell cultures of prion infectivity

1 reference

https://api.crossref.org/works/10.1038%2FNATURE01870

7 January 2021

Monoclonal antibodies inhibit prion replication and delay the development of prion disease

1 reference

https://api.crossref.org/works/10.1038%2FNATURE01870

7 January 2021

Models of amyloid seeding in Alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins

1 reference

https://api.crossref.org/works/10.1038%2FNATURE01870

7 January 2021

Two simple methods for quantifying low-affinity dye-substrate binding.

1 reference

https://api.crossref.org/works/10.1038%2FNATURE01870

7 January 2021

Partial denaturation of transthyretin is sufficient for amyloid fibril formation in vitro

1 reference

https://api.crossref.org/works/10.1038%2FNATURE01870

7 January 2021

Amyloid fibril formation and seeding by wild-type human lysozyme and its disease-related mutational variants.

1 reference

https://api.crossref.org/works/10.1038%2FNATURE01870

7 January 2021

Common core structure of amyloid fibrils by synchrotron X-ray diffraction.

1 reference

https://api.crossref.org/works/10.1038%2FNATURE01870

7 January 2021

Interventional strategies against prion diseases

1 reference

https://api.crossref.org/works/10.1038%2FNATURE01870

7 January 2021

Therapeutic strategies for Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1038%2FNATURE01870

7 January 2021

Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis

1 reference

https://api.crossref.org/works/10.1038%2FNATURE01870

7 January 2021

Protein folding and disease: a view from the first Horizon Symposium.

1 reference

https://api.crossref.org/works/10.1038%2FNATURE01870

7 January 2021

Potent inhibition of scrapie prion replication in cultured cells by bis-acridines

1 reference

https://api.crossref.org/works/10.1038%2FNATURE01870

7 January 2021

Screening transthyretin amyloid fibril inhibitors: characterization of novel multiprotein, multiligand complexes by mass spectrometry

1 reference

https://api.crossref.org/works/10.1038%2FNATURE01870

7 January 2021

Prevention of transthyretin amyloid disease by changing protein misfolding energetics.

1 reference

https://api.crossref.org/works/10.1038%2FNATURE01870

7 January 2021

Expression, purification, and characterization of the recombinant calcium-binding equine lysozyme secreted by the filamentous fungus Aspergillus niger: comparisons with the production of hen and human lysozymes

1 reference

https://api.crossref.org/works/10.1038%2FNATURE01870

7 January 2021

1H and 15N NMR Study of Human Lysozyme

1 reference

https://api.crossref.org/works/10.1038%2FNATURE01870

7 January 2021

MOLMOL: a program for display and analysis of macromolecular structures

1 reference

https://api.crossref.org/works/10.1038%2FNATURE01870

7 January 2021